neuro-primary-mental-health-2017-scientifictracks

16 / 22

Page 39
Notes:
allied
academies
17th International Conference on 4 th International Conference on
NEUROLOGY AND NEUROSCIENCE & MENTAL HEALTH AND PRIMARY CARE
October 16-18, 2017 | Toronto, Canada
J Neurol Neurorehabil Res 2017 | Volume 2 Issue 3
Regenerage system: therapeutic effects of combinatorial biologics (Bioquantine®) and spinal cord
stimulation system on a patient with spinal cord section
Joel I Osorio
Westhill University School of Medicine, Mexico
As it has been previously demonstrated that co-
electroporation of Xenopus laevis frog oocytes with
normal cells and cancerous cell lines induces the expression
of pluripotency markers, and in experimental murine
model studies that Bioquantine® extract (purified from
intra- and extra-oocyte liquid phases of electroporated
oocytes) showed potential as a treatment for a wide range
of conditions as Squint, Spinal Cord Injury (SCI) and Cerebral
Palsy among others. The current study observed beneficial
changes with Bioquantine® administration in a patient with
a severe SCI. Pluripotent stem cells have therapeutic and
regenerative potential in clinical situations CNS disorders
even cancer. One method of reprogramming somatic cells
into pluripotent stem cells is to expose them to extracts
prepared fromXenopus laevis showedpreviously
that coelectroporation of Xenopus laevis frog oocytes; with
normal cells and cancerous cell lines, induces expression of
markersof pluripotency.Wealsoobserved therapeuticeffects
of treatment with a purified extract (Bioquantine) of intra-
and extra-oocyte liquid phases derived from electroporated
X. laevis oocytes, on experimentally induced pathologies
including murine models of melanoma, traumatic brain
injury, and experimental skin wrinkling induced by squalene-
monohydroperoxide. The positive human findings for Spinal
Cord Injury and Cerebral Palsy with the results from previous
animal studies with experimental models of traumatic
brain injury, respectively. Because of ethical reasons, legal
restrictions, and a limited numbers of patients, we were able
to treat only a very small number of patients. These results
indicate that Bioquantine® may be safe and well tolerated
for use in humans, and deserves further study in a range of
degenerative disorders. We propose that the mechanism of
action of Bioquantine® in these various diseases derives from
its unique pharmacology and combinatorial reprogramming
properties. In conclusion, these preliminary findings suggest
that Bioquantine is safe and well tolerated on patients with
Cerebral Palsy and Spinal Cord Injury, among others. In
addition to the regenerative therapy and due to the patient
condition,wedecided to include theRestoreSensor SureScan.
Based on the of electrical stimulation for rehabilitation and
regeneration after spinal cord injury published by Hamid and
MacEwan, we designed an improved delivery method for the
in situ application of MSCs and Bioquantine® in combination
with the RestoreSensor® SureScan® Conclusions: To the
present day the patient who suffered a total section of
spinal cord at T12-L1 shows an improvement in sensitivity,
strength in striated muscle and smooth muscle connection,
9 months after the first therapy of cell regeneration and 1
month after the placement of RestoreSensor® at the level
of the lesion, the patient with a complete medullary section
shows an evident improvement on his therapy of physical
rehabilitation in standing for the first time and showing a
progressively important functionality.
Speaker Biography
Joel I Osorio is the CEO & Founder - Biotechnology and Regenerative Medicine at
RegenerAge International ™ .VP of International Clinical
Development for Bioquark, Inc. ).Chief Clinical Officer at
ReAnima™ Advanced Biosciences ) Westhill University School
of Medicine. Mexico .Advance Fellow by the American Board of AntiAging and
Regenerative Medicine (A4M)Visiting scholar at University of North Carolina at Chapel
Hill (Dermatology)Fellow in Stem Cell Medicine by the American Academy of Anti-
Aging Medicine and University of South Florida.
e: